Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
View Publication
Export 
BiBTeXSEEK ID: https://fdm.digital-medicine.org/publications/10
DOI: 10.1016/S0140-6736(18)31791-4
Trial Projects: Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy...
Publication type: Journal
Journal: The Lancet
Citation: The Lancet 393(10172):678-688
Date Published: 1st Feb 2019
Registered Mode: by DOI
Export PNG
Download
SubmitterViews: 524
Created: 28th Nov 2024 at 14:22
Last updated: 28th Nov 2024 at 14:22
TagsThis item has not yet been tagged.
AttributionsNone
Related items
Trial Projects:
- Postoperative Ileus: Duration and Severity Assessment With the SmartPill® (PIDuSA)
- Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study (RIP)
- Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients (CeTeG)
- Chromoendoskopie versus konventionelle Endoskopie bei Patienten mit Polyposis-Erkrankungen (ChroPol)
- A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)
- Echtzeit-Nutzung von automatisierter Intelligenz (CADEYE) bei der Darmkrebs-Überwachung von Patienten mit Lynch-Syndrom
Institutions: University Hospital Bonn Department of Surgery, University Hospital Bonn Department of Ophthalmology, Default Institution
The prognosis of patients with newly diagnosed glioblastoma is dismal despite recent therapeutic improvements Using standard therapy with temozolomide (TMZ) and radiotherapy (60 Gy), the median overall survival time (mOS) is 14.6 months (Stupp et al., 2005). Since in a previous non-randomized bicentric phase II trial, primary combination chemotherapy with lomustine (CCNU) and TMZ was highly effective (mOS 23 months; UKT-03 trial; Herrlinger et al., 2006; Glas et al., 2009) the proposed trial ...
Public web page: https://clinicaltrials.gov/study/NCT01149109
Start date: 1st Oct 2010
End date: 6th Apr 2017
